Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH

Hepatology

From "Burnt-Out" to "Burning-Out": Capturing Liver Fat Loss in Patients with Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease from A Dynamic Perspective

Gastroenterology

Liu WY, Huang S, Ji H, Kim SU, Cheuk-Fung Yip T, Lai-Hung Wong G, Petta S, Tsochatzis E, Nakajima A, Bugianesi E, George Goh BB, Chan WK, Romero-Gomez M, Sanyal AJ, Boursier J, Hagström H, Calleja JL, de Lédinghen V, Newsome PN, Fan JG, Lai M, Castéra L, Lee HW, Pennisi G, Yoneda M, Armandi A, Kim-Jun Teh K, Gallego-Durán R, Asgharpour A, de Saint-Loup M, Shang Y, Llop E, Fournier C, Mahgoub S, Lara-Romero C, Canivet CM, Sau-Wai Chan M, Lin H, Chen LL, Targher G, Byrne CD, Du M, Wai-Sun Wong V, Zheng MH, VCTE-Prognosis Study Group

doi: 10.1053/j.gastro.2025.02.034

Hepatology

Longitudinal response to standard of care in pediatric metabolic dysfunction-associated steatotic liver disease: Rates of improvement and worsening, and factors associated with outcomes

Hepatology

Newton KP, Jayasekera D, Blackford AL, Behling C, Wilson LA, Fishbein MH, Molleston JP, Xanthakos SA, Vos MB, Schwimmer JB, NASH CRN

doi: 10.1097/HEP.0000000000001216

Esophagus Diseases

Histologic response is associated with improved esophageal distensibility and symptom burden in pediatric eosinophilic esophagitis

Gastroenterology

Kennedy K, Burger C, Pan Z, Umeweni CN, Alston M, Benitez A, Furuta GT, Mahon M, Ruffner MA, Quinn L, Muir A, Menard-Katcher C

doi: 10.1053/j.gastro.2025.07.042

Hepatitis

Estimation of the Eligible Population For Resmetirom Among Adults in the United States for Treatment of Non-Cirrhotic NASH with Moderate-to-Advanced Liver Fibrosis

Adv Ther

Fishman J, Kim Y, Charlton MR, Smith ZJ, O'Connell T, Bercaw EM

doi: 10.1007/s12325-024-02989-5

Helicobacter Pylori

Vonoprazan Improves Efficacy of Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter Randomized Controlled Trial

Helicobacter

Yan TL, Wang JH, Zhu RK, Zhai HL, Wang ZZ, Mao XL, Shen X, Xu P, Ma D, He XJ, Wang JW, Gao JG, Jiang LL, Sun K, Chen Y, Sang JZ, Liu XQ, Chen JE, Li L

doi: 10.1111/hel.70056

Hepatology

Steatotic liver disease classification is dynamic, affecting clinical trial eligibility and subclass-specific treatments

Clin Gastroenterol Hepatol

Israelsen M, Thorhauge KH, Andersen P, Johansen S, Schnefeld HL, Bech KT, Hansen JK, Torp N, Jensen EL, Hansen ED, Spedtsberg IZ, Villesen IF, Hansen CD, Hansen T, Lindvig KP, Thiele M, Krag A

doi: 10.1016/j.cgh.2025.02.007

Hepatology

Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases: Target trial emulation using real-world data

Hepatology

Ng WH, Yeo YH, Kim H, Seki E, Rees J, Ma KS, Moylan CA, Rodriquez LM, Abdelmalek M, Villanueva A, Noureddin M, Yang JD

doi: 10.1097/HEP.0000000000001333

Gastrointestinal Cancer

Immune-related Adverse Events are Associated with Improved Outcomes after Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

Am J Gastroenterol

Hwang SY, Rezaee-Zavareh MS, Attia AM, Kaymen EA, Tran N, Abou-Alfa GK, Parikh ND, Singal AG, Yang JD

doi: 10.14309/ajg.0000000000003546

Hepatology

The liver-brain axis in metabolic dysfunction-associated steatotic liver disease

Lancet Gastroenterol Hepatol

Mikkelsen ACD, Kjærgaard K, Schapira AHV, Mookerjee RP, Thomsen KL

doi: 10.1016/S2468-1253(24)00320-0

Related content

From "Burnt-Out" to "Burning-Out": Capturing Liver Fat Loss in Patients with Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease from A Dynamic Perspective

Longitudinal response to standard of care in pediatric metabolic dysfunction-associated steatotic liver disease: Rates of improvement and worsening, and factors associated with outcomes

Histologic response is associated with improved esophageal distensibility and symptom burden in pediatric eosinophilic esophagitis

Estimation of the Eligible Population For Resmetirom Among Adults in the United States for Treatment of Non-Cirrhotic NASH with Moderate-to-Advanced Liver Fibrosis

Vonoprazan Improves Efficacy of Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter Randomized Controlled Trial

Steatotic liver disease classification is dynamic, affecting clinical trial eligibility and subclass-specific treatments

Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases: Target trial emulation using real-world data

Immune-related Adverse Events are Associated with Improved Outcomes after Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

The liver-brain axis in metabolic dysfunction-associated steatotic liver disease